Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05954871
Other study ID # GO44272
Secondary ID 2022-502530-10-0
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 8, 2024
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source Genentech, Inc.
Contact Reference Study ID Number: GO44272 https://forpatients.roche.com
Phone 888-662-6728 (U.S. Only)
Email global-roche-genentech-trials@gene.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.


Recruitment information / eligibility

Status Recruiting
Enrollment 172
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Evaluable or measurable disease per RECIST v1.1 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Life expectancy of =12 weeks - Adequate hematologic and organ function within 14 days prior to initiation of study Inclusion Criteria for Non-Small Cell Lung Cancer Cohorts - Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the lung that has progressed on/after prior treatment with third-generation epidermal growth factor receptor (EGFR) inhibitor (e.g., osimertinib) - Positive for an EGFR exon 19 deletion or exon 21 L858R mutation - Negative for acquired on-target EGFR alterations Inclusion Criteria for Colorectal Cancer Cohorts - Histologically confirmed metastatic adenocarcinoma of the colon or rectum that has progressed on/after prior treatment with an EGFR inhibitor (e.g., cetuximab or panitumumab) - Negative for kirsten rat sarcoma viral oncogene homolog (KRAS) alterations - Negative for neuroblastoma RAS viral oncogene homolog (NRAS) alterations - Negative for proto-oncogene B-Raf (BRAF) V600E alterations - In lieu of a fresh pre-treatment biopsy, a recently obtained biopsy performed after completion of osimertinib therapy will be acceptable Exclusion Criteria: - Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 3 weeks or 5 drug elimination half-lives, whichever is shorter, prior to initiation of study treatment - Treatment with endocrine therapy within 2 weeks prior to initiation of study drug, except for hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for endocrine-sensitive cancers - Significant traumatic injury or major surgical procedure within 4 weeks prior to Cycle 1, Day 1 - Positive hepatitis C virus (HCV) antibody test at screening - Positive hepatitis B surface antigen (HBsAg) test at screening - Known HIV infection - Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis - Uncontrolled hypercalcemia - Substance abuse, as determined by the investigator, within 12 months prior to screening - Poor peripheral venous access - Inability or unwillingness to swallow pills - Malabsorption syndrome or other condition that would interfere with enteral absorption Chronic diarrhea, short bowel syndrome, or significant upper GI surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or any active bowel inflammation (including diverticulitis) - Serious infection within 4 weeks prior to screening - History of malignancy within 3 years prior to screening - Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) - Leptomeningeal disease or carcinomatous meningitis - History or presence of an abnormal electrocardiogram (ECG) that is deemed clinically significant by the investigator (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence of prior myocardial infarction - Left ventricular ejection fraction (LVEF) less than the institutional lower limit of normal (LLN) or <50% - History or evidence of ophthalmic disease - History of or active clinically significant cardiovascular dysfunction - History of pulmonary firbrosis, organizing pneumonia, or pneumonitis Other protocol-defined inclusion/exclusion criteria may apply.

Study Design


Intervention

Drug:
GDC-1971
GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
Osimertinib
Osimertinib tablets will be administered as specified in each treatment arm.
Cetuximab
Cetuximab, solution for infusion will be administered as specified in each treatment arm.

Locations

Country Name City State
Australia St Vincent's Hospital Melbourne Fitzroy Victoria
Australia Border Medical Oncology Wodonga New South Wales
Australia The Queen Elizabeth Hospital Woodville South Australia
Canada Ottawa Hospital Ottawa Ontario
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
United States SCRI Oncology Partners Nashville Tennessee
United States Yale Cancer Center New Haven Connecticut
United States Christiana Care Health System Newark Delaware
United States START South Texas Accelerated Research Therapeutics-San Antonio San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Up to approximately 41 months
Primary Number of Participants with Dose-Limiting Toxicities (DLTs) Day 1 through Day 28 of Cycle 1 (1cycle= 28 days)
Secondary Plasma Concentration of GDC-1971 Up to approximately 41 months
Secondary Plasma Concentration of Osimertinib Up to approximately 41 months
Secondary Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Up to approximately 41 months
Secondary Duration of Response (DOR) as Determined by Investigator According to RECIST v1.1 Up to approximately 41 months
Secondary Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1 Up to approximately 41 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A